|
|
Market Dynamics 2001: Hepatitis B&C - The Succession of New Generation TherapiesPublished by: Datamonitor Published: Jul. 1, 2001 - 143 Pages Table of ContentsMarket Dynamics 2001: Hepatitis B&C - The Succession of New Generation Therapies Scope Datamonitor insight into the hepatitis market Key metrics PATIENT POTENTIAL Disease definition Hepatitis B Hepatitis C Trends in the epidemiology of Hepatitis B & C Hepatitis B Hepatitis C The incidence of Hepatitis B & C The prevalence of Hepatitis B & C Natural history and diagnosis of Hepatitis B & C Hepatitis B Hepatitis C Classification of Hepatitis B & C Hepatitis B Hepatitis C Treatment and prevention guidelines in Hepatitis B & C Treatment and prevention of HBV Treatment and prevention of HCV GLOBAL MARKET ANALYSIS Treatment of hepatitis B & C Hepatitis B & C drug class definitions Interferons Nucleoside analogs Immunomodulators Vaccines Class comparisons Hepatitis B & C market analysis by drug class Overview of global hepatitis B & C market Key trends in the global Hepatitis B & C market Interferons Overview of the global interferons market Key trends in the global interferon market Intron-A Roferon-A Rebetron Nucleoside analogs Overview of the global nucleoside analog market Key trends in the global nucleoside analog market Rebetol Zeffix Serocion Vaccines Overview of the global vaccines market Key trends in the global vaccines market Engerix-B Recombivax Immunomodulators Zadaxin GLOBAL PLAYERS IN THE HEPATITIS MARKET Global analysis Key trends in the global Hepatitis B & C markets by company Therapy area portfolios of the leading companies in hepatitis Schering-Plough GlaxoSmithKline Hoffmann-La Roche Global company positioning in the hepatitis B & C market COUNTRY MARKET ANALYSIS Significance of major countries in the global Hepatitis B & C market Overview of the global Hepatitis B & C market Breakdown of the country markets by class Global Environmental Drivers The US Hepatitis B & C market Environmental factors influencing the US hepatitis market US company analysis The Japanese Hepatitis Market Environmental factors influencing the Japanese hepatitis market Japanese company analysis The French Hepatitis Market Environmental factors influencing the French hepatitis market French company analysis The German Hepatitis Market Environmental factors influence the German hepatitis market German company analysis The Italian Hepatitis Market Environmental factors influence the Italian hepatitis market Italian company analysis The Spanish Hepatitis Market Environmental factors influence the Spanish hepatitis market Spanish company analysis The UK Hepatitis Market Environmental factors influencing the UK hepatitis market UK company analysis LIFECYCLE MANAGEMENT Global drug class lifecycle in Hepatitis B & C Reformulations in Hepatitis B & C Lifecycle management case studies MARKET FORECASTS Forecasting methodology Hepatitis disease market growth Hepatitis disease drug class growth Individual hepatitis drug growth Future trends in the incidence and prevalence of hepatitis Trends in the Hepatitis B & C market to 2008 Forecast overview The overall hepatitis market 2000-2008 The hepatitis vaccines market Product forecasts APPENDIX Research program methodology SPRINT databases Primary Research Quantification of Data Reliability Strategic Issues and Opinion Surveys Lists of tables List of figures (c) Datamonitor 2000. All Rights Reserved. AbstractThe rising prevalence of hepatitis C coupled with the poor efficacy of existing treatments has led to the development of longer-acting interferons. The uptake of these agents together with the move away from interferon-based treatment of hepatitis B will see a decline in sales of standard interferons, leading to an increasingly polarized market until the emergence of new treatment options after 2004. Market Dynamics 2001: Hepatitis features an in-depth analysis of the HBV and HCV markets to 2008, covering the continued co-dominance of Schering-Plough and Roche. The report provides comprehensive coverage of the seven major pharmaceutical markets (the US, Japan, France, Germany, Italy, Spain, and the UK) with an in-depth analysis of the current and future commercial attractiveness of the hepatitis market to manufacturers of vaccines and treatments.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||